The BRAF mutational status was determined based on a next-generation sequencing panel in 56.7% of cases, on a targeted multiplex PCR in 33.8% of cases, on circulating tumor DNA in 2.0% of cases, and with an unknown or another method in 7.5% of cases. The gene discussed is BRAF; the disease is neoplasm.